Notice of Results

RNS Number : 1444V

Intelligent Ultrasound Group PLC

08 August 2022

 

Intelligent Ultrasound Group plc

(the "Group" or the "Company")

Notice of results

Analyst and investor briefing

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces it will issue its interim results for the six months ended 30 June 2022 on Thursday 18, August 2022.

A briefing for analysts will be held via Zoom on 18 August 2022 at 9.30am. To register, please contact Walbrook PR at [e-mail] .

The Company will host a live presentation for investors given by Stuart Gall and Helen Jones via the Investor Meet Company platform on Friday, 19 August 2022 at 2.30pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet the Company via: https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor

Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Intelligent Ultrasound Group plc			www.  intelligentultrasound.com
Stuart Gall, CEO			Tel: [phone]
Helen Jones, CFO
Cenkos Securities - Nominated Advisor and Broker
Giles Balleny/Max Gould (Corporate Finance)				Tel:  [phone]
Michael Johnson/Julian Morse (Sales)
Walbrook PR	Tel: [phone] or  [e-mail]
Anna Dunphy			Mob: [phone]

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.  Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,400 simulators have been sold to c. 700 medical institutions around the world.

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy   highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.  

www.intelligentultrasound.com

NOTE: ScanNav Anatomy PNB is CE approved, but not yet available for sale in the US or any other territory requiring government approval for this type of product.

 

END

 

 

NORZZGGRDKKGZZM